2024-04-02 16:25:53
A groundbreaking clinical trial led by researchers from Massachusetts General Hospital provides promising insights into the management of metabolic-associated fatty liver disease (MASLD), the most prevalent chronic liver condition in the United States.
The study, published in JAMA, highlights the potential of aspirin as a low-cost treatment option for fatty liver disease associated with metabolic dysfunction, which affects up to one-third of adults in the United States.
Lead author Andrew T. Chan conducted a phase 2 trial that included 80 adults with metabolically impaired fatty liver disease who were randomly assigned to receive daily low-dose aspirin or a placebo for six months.
The results revealed a significant reduction in liver fat content among participants who took aspirin, compared to those who took a placebo. Furthermore, aspirin was considered safe and well-tolerated, with improvements observed in various markers of liver health.
Lead author Tracey Simon confirmed the continued benefits of aspirin across several non-invasive tests, suggesting its potential to mitigate long-term complications associated with metabolic dysregulation of fatty liver disease.
While further studies are warranted to confirm the sustained efficacy of aspirin in the management of this disease, these results represent a critical step toward meeting the urgent need for effective treatments for this common liver disease.
Suggest a correction
2024-04-02 16:25:53